AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
InflaRx shares surge 13.13% after-hours as Raymond James raises price target to $9 on positive HS trial data.
ByAinvest
Tuesday, Nov 11, 2025 5:05 pm ET1min read
InflaRx surged 13.13% in after-hours trading following Raymond James raising its price target to $9 from $2 and Cantor Fitzgerald lifting its target to $8 from $3, both citing strong Phase 2a data for INF904 in hidradenitis suppurativa (HS). The drug demonstrated a 63% HiSCR50 response rate at Week 8 for the 120mg BID dose, with significant pain score improvements (75%) outperforming competitors. Raymond James highlighted INF904’s potential in HS and complement-driven autoimmune diseases, while H.C. Wainwright initiated coverage with a $6 Buy rating. The stock’s rally also aligned with regained Nasdaq compliance and anticipation of Q3 2025 results on November 10. Analyst optimism and positive clinical data directly supported the sharp after-hours gain.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet